Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions

Abstract

LEBT demonstrated significant responses at very low doses without additional toxicity in patients on protocol treatment with the histone deacetylase inhibitor romidepsin. This merits formal investigation in a clinical trial for potential synergy in patients with CTCL.